find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
Lymphoma
N/A
Enrolling
nct/study# N/A / 2019-0748
Retrospective Analysis of intensive chemotherapy (modified Hyper-CVAD) in aggressive Non-Hodgkin Lymphoma patients – CNS outcomes
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / 2020-0377
Examining COVID19 course and outcomes in patients previously diagnosed with chronic lymphocytic leukemia (CLL)
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / 2020-0487
Molecular Profiling of Diffuse Large B Cell Lymphoma and Acute Leukemias Treated with Dose Intense Regimens
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / 2021-0081
Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell Patients: Real World Experience in Lymphoma Patients
Learn More
Lymphoma
Phase III
Enrolling
nct/study# NCT06561048 / CPI-818-004
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physicians Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Learn More
Lymphoma
Phase I/II
Enrolling
nct/study# NCT06542250 / D9960CC00001
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.